JB
FATE icon

Julian Baker’s Fate Therapeutics FATE Stock Holding History

Julian Baker’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,485,018
Closed -$2.78M – 93
2025
Q2 		$2.78M Sell
2,485,018
-773,384
-24% -$899K 0.03% 72
2025
Q1 		$2.57M Hold
3,258,402
– – 0.03% 71
2024
Q4 		$5.38M Buy
3,258,402
+260,630
+9% +$657K 0.06% 66
2024
Q3 		$10.5M Hold
2,997,772
– – 0.11% 51
2024
Q2 		$9.83M Buy
2,997,772
+1,179,591
+65% +$5.16M 0.13% 48
2024
Q1 		$13.3M Buy
+1,818,181
New +$11.3M 0.17% 44
2023
Q3 		– Sell
-1,671,717
Closed -$7.96M – 103
2023
Q2 		$7.96M Hold
1,671,717
– – 0.05% 63
2023
Q1 		$9.53M Buy
1,671,717
+1,456,022
+675% +$8.79M 0.05% 55
2022
Q4 		$2.18M Hold
215,695
– – 0.01% 97
2022
Q3 		$4.83M Buy
+215,695
New +$6.23M 0.03% 82

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wilshire Advisors Santa Monica, California $10.3M AUM 79.91% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Julian Baker's FATE Position: Q3 2025 in Review

Julian Baker sold out of Fate Therapeutics (FATE) in Q3 2025, closing a stake of 2,485,018 shares — an estimated $2.78M sold.

Julian Baker first reported a position in FATE in Q3 2022 and held it in 10 quarters. The position peaked at $13.3M in Q1 2024. 143 funds tracked by Wall St. Rank hold FATE as of Q3 2025.

  • Julian Baker reported no remaining Fate Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Julian Baker sold 2,485,018 Fate Therapeutics shares in Q3 2025, an estimated $2.78M.
  • Julian Baker first reported a position in Fate Therapeutics in Q3 2022 and held it in 10 quarters.
  • Julian Baker's Fate Therapeutics position peaked at $13.3M in Q1 2024.
  • 143 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2025.

Based on Baker Bros. Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.